Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V
| Autor: | M. A. Chirskaya, D. A. Gusev, N.V. Dunaeva, V. E. Karev, Sergey V. Lapin, S. Yu. Romanova, E. Yu. Kolpashchikova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Elbasvir
medicine.medical_specialty Daclatasvir Sofosbuvir Infectious and parasitic diseases RC109-216 Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine 030212 general & internal medicine Cryoglobulinemic vasculitis chronic hepatitis c cryoglobulinemia cryoglobulinemic vasculitis elbasvir grazoprevir sofosbuvir daclatasvir asunaprevir mutations resistance business.industry medicine.disease Cryoglobulinemia Infectious Diseases chemistry Grazoprevir Asunaprevir 030211 gastroenterology & hepatology business Vasculitis medicine.drug |
| Zdroj: | Žurnal Infektologii, Vol 12, Iss 1, Pp 104-110 (2020) |
| ISSN: | 2072-6732 |
| DOI: | 10.22625/2072-6732-2020-12-1-104-110 |
| Popis: | The case of chronic hepatitis C 1b genotype with grade 3 fibrosis according to Metavir, complicated by the development of mixed type III cryoglobulinemia, cryoglobulinemic vasculitis with damage to the skin vessels of the skin (hemorrhagic vasculitis), and the liver (alternatively proliferative vasculitis) is demonstrated. The introduction of daclatasvir + asunaprevir was virologically unsuccessful: mutations D168E and L31V were detected against the background of a virological breakthrough. A repeated course of antiviral therapy with the combination of Grazoprevir + Elbasvir in combination with sofosbuvir led to a stable virologic response, partial immunological and clinical remission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|